Spots Global Cancer Trial Database for modified folfox6
Every month we try and update this database with for modified folfox6 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | NCT03343301 | Gastrointestina... Gastrointestina... Gastric Cancer | Bemarituzumab Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | NCT00625651 | Metastatic Colo... Colon Cancer Colorectal Canc... Rectal Cancer | Placebo AMG 655 Modified FOLFOX... Bevacizumab | 18 Years - | Amgen | |
| Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | NCT04952753 | Metastatic Colo... | NIS793 Bevacizumab Modified FOLFOX... FOLFIRI Tislelizumab | 18 Years - | Novartis | |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | NCT00625651 | Metastatic Colo... Colon Cancer Colorectal Canc... Rectal Cancer | Placebo AMG 655 Modified FOLFOX... Bevacizumab | 18 Years - | Amgen | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer | NCT03694522 | Gastric Cancer | Bemarituzumab Placebo Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer | NCT02142322 | Advanced Gastri... | MODIFIED FOLFOX... | 18 Years - | Seoul National University Hospital | |
| Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer | NCT02142322 | Advanced Gastri... | MODIFIED FOLFOX... | 18 Years - | Seoul National University Hospital | |
| Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases | NCT01646554 | Colorectal Canc... Liver Metastase... KRAS Mutated Co... | Modified FOLFOX... Aflibercept Surgery | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | NCT03343301 | Gastrointestina... Gastrointestina... Gastric Cancer | Bemarituzumab Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | NCT03798626 | Colorectal Canc... Gastroesophagea... Renal Cell Carc... | Gevokizumab Bevacizumab Modified FOLFOX... FOLFIRI Ramucirumab Paclitaxel Cabozantinib | 18 Years - | Novartis | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | NCT03343301 | Gastrointestina... Gastrointestina... Gastric Cancer | Bemarituzumab Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer | NCT03694522 | Gastric Cancer | Bemarituzumab Placebo Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
